Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 32 | 2024 | 234 | 4.410 |
Why?
|
| Severity of Illness Index | 9 | 2015 | 1917 | 0.730 |
Why?
|
| Sjogren's Syndrome | 4 | 2020 | 34 | 0.520 |
Why?
|
| Cyclophosphamide | 2 | 2014 | 278 | 0.450 |
Why?
|
| Biological Factors | 1 | 2014 | 18 | 0.440 |
Why?
|
| Autoantibodies | 9 | 2020 | 277 | 0.430 |
Why?
|
| Patient Preference | 2 | 2014 | 125 | 0.430 |
Why?
|
| Health Status | 4 | 2013 | 377 | 0.410 |
Why?
|
| Antirheumatic Agents | 2 | 2012 | 59 | 0.400 |
Why?
|
| Tachycardia | 1 | 2013 | 38 | 0.390 |
Why?
|
| Lupus Nephritis | 4 | 2024 | 78 | 0.380 |
Why?
|
| Interferon-alpha | 7 | 2012 | 187 | 0.370 |
Why?
|
| Academic Medical Centers | 2 | 2013 | 394 | 0.370 |
Why?
|
| Patient Care Planning | 1 | 2012 | 87 | 0.350 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 117 | 0.350 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 124 | 0.350 |
Why?
|
| Minority Groups | 1 | 2012 | 149 | 0.340 |
Why?
|
| Cognition Disorders | 3 | 2015 | 236 | 0.280 |
Why?
|
| Adult | 25 | 2024 | 27918 | 0.280 |
Why?
|
| Sick Leave | 1 | 2008 | 15 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 2465 | 0.270 |
Why?
|
| Blood Viscosity | 1 | 2007 | 14 | 0.260 |
Why?
|
| Rheumatology | 1 | 2007 | 39 | 0.260 |
Why?
|
| Specialization | 1 | 2007 | 67 | 0.260 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 56 | 0.250 |
Why?
|
| Decision Making | 1 | 2012 | 674 | 0.250 |
Why?
|
| Career Choice | 1 | 2007 | 156 | 0.240 |
Why?
|
| Female | 30 | 2024 | 48698 | 0.240 |
Why?
|
| Injections | 1 | 2006 | 124 | 0.240 |
Why?
|
| Physical Examination | 1 | 2006 | 144 | 0.230 |
Why?
|
| Male | 26 | 2024 | 44553 | 0.220 |
Why?
|
| Humans | 40 | 2024 | 93511 | 0.220 |
Why?
|
| Middle Aged | 18 | 2024 | 27569 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2018 | 2484 | 0.210 |
Why?
|
| Thrombosis | 1 | 2007 | 309 | 0.210 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2004 | 3 | 0.210 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 543 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2013 | 1847 | 0.190 |
Why?
|
| Internal Medicine | 1 | 2006 | 336 | 0.190 |
Why?
|
| Muromonab-CD3 | 1 | 2002 | 70 | 0.190 |
Why?
|
| Arthritis, Psoriatic | 1 | 2002 | 36 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 259 | 0.180 |
Why?
|
| Quality of Life | 3 | 2012 | 1780 | 0.170 |
Why?
|
| Chicago | 4 | 2014 | 1464 | 0.170 |
Why?
|
| Osteopontin | 2 | 2011 | 48 | 0.160 |
Why?
|
| Internship and Residency | 2 | 2007 | 1090 | 0.160 |
Why?
|
| B-Lymphocytes | 4 | 2018 | 701 | 0.160 |
Why?
|
| Prevalence | 4 | 2016 | 1321 | 0.150 |
Why?
|
| Pain Measurement | 3 | 2006 | 373 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 557 | 0.140 |
Why?
|
| Antibodies, Antinuclear | 4 | 2020 | 94 | 0.140 |
Why?
|
| Major Histocompatibility Complex | 1 | 2018 | 86 | 0.140 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 576 | 0.140 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2018 | 35 | 0.140 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2018 | 87 | 0.130 |
Why?
|
| Risk Factors | 5 | 2014 | 5898 | 0.130 |
Why?
|
| Illinois | 2 | 2012 | 520 | 0.130 |
Why?
|
| Adolescent | 8 | 2024 | 9606 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 555 | 0.120 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 1 | 0.120 |
Why?
|
| Inflammation | 4 | 2020 | 1050 | 0.120 |
Why?
|
| Phenotype | 5 | 2020 | 2544 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 28 | 0.120 |
Why?
|
| Comorbidity | 2 | 2013 | 1007 | 0.120 |
Why?
|
| Gene Expression | 1 | 2020 | 1301 | 0.120 |
Why?
|
| Genome-Wide Association Study | 4 | 2012 | 1762 | 0.120 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2015 | 11 | 0.110 |
Why?
|
| Macula Lutea | 1 | 2015 | 17 | 0.110 |
Why?
|
| Young Adult | 7 | 2024 | 6930 | 0.110 |
Why?
|
| Nerve Fibers | 1 | 2015 | 40 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2013 | 579 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 990 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 300 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 1395 | 0.110 |
Why?
|
| Epitopes | 2 | 2018 | 254 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 1994 | 36 | 0.110 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2016 | 183 | 0.110 |
Why?
|
| Research Subjects | 1 | 2014 | 73 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 1994 | 225 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 149 | 0.100 |
Why?
|
| Tetanus Toxoid | 1 | 2012 | 10 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 373 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 33 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2802 | 0.090 |
Why?
|
| Cytokines | 2 | 2020 | 863 | 0.090 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2011 | 32 | 0.090 |
Why?
|
| Aged | 7 | 2024 | 20430 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2011 | 3054 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 44 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 210 | 0.080 |
Why?
|
| Attitude to Health | 1 | 2012 | 217 | 0.080 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 72 | 0.080 |
Why?
|
| Cicatrix | 1 | 2011 | 74 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2010 | 36 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2012 | 168 | 0.080 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 962 | 0.080 |
Why?
|
| Patient Selection | 1 | 2014 | 690 | 0.080 |
Why?
|
| Self Report | 1 | 2012 | 328 | 0.080 |
Why?
|
| Kidney Tubules | 1 | 2010 | 91 | 0.080 |
Why?
|
| Anxiety | 1 | 2013 | 337 | 0.080 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 322 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2018 | 970 | 0.080 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2010 | 3 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2024 | 9098 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 960 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 608 | 0.080 |
Why?
|
| Chemokine CXCL13 | 2 | 2020 | 17 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 282 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1103 | 0.070 |
Why?
|
| Kidney | 1 | 2014 | 1111 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 2010 | 613 | 0.070 |
Why?
|
| Autoimmunity | 1 | 2010 | 189 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2013 | 1006 | 0.070 |
Why?
|
| Depression | 1 | 2013 | 544 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2010 | 176 | 0.070 |
Why?
|
| Marital Status | 1 | 2008 | 43 | 0.070 |
Why?
|
| Alleles | 4 | 2011 | 1139 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 2008 | 53 | 0.070 |
Why?
|
| Outpatients | 1 | 2008 | 104 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2011 | 1415 | 0.070 |
Why?
|
| Educational Status | 1 | 2008 | 197 | 0.070 |
Why?
|
| Rheology | 1 | 2007 | 38 | 0.070 |
Why?
|
| Fatigue | 1 | 2008 | 181 | 0.060 |
Why?
|
| Interleukins | 2 | 2020 | 133 | 0.060 |
Why?
|
| Urban Population | 1 | 2008 | 234 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1518 | 0.060 |
Why?
|
| Models, Anatomic | 1 | 2006 | 87 | 0.060 |
Why?
|
| Joint Diseases | 1 | 2006 | 47 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1729 | 0.060 |
Why?
|
| Nephritis | 1 | 2005 | 17 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2006 | 188 | 0.060 |
Why?
|
| Registries | 1 | 2010 | 990 | 0.060 |
Why?
|
| Knee Joint | 1 | 2006 | 161 | 0.060 |
Why?
|
| Shoulder Joint | 1 | 2006 | 98 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 7061 | 0.050 |
Why?
|
| Education, Medical | 1 | 2007 | 228 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2006 | 193 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2006 | 315 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1161 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 1713 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2006 | 238 | 0.050 |
Why?
|
| Autoantigens | 2 | 2018 | 138 | 0.050 |
Why?
|
| Sex Factors | 3 | 2010 | 1105 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2004 | 12 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2024 | 85 | 0.050 |
Why?
|
| Linear Models | 1 | 2004 | 413 | 0.050 |
Why?
|
| Genotype | 3 | 2011 | 1866 | 0.040 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 255 | 0.040 |
Why?
|
| Ribonucleoproteins | 2 | 2011 | 36 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 829 | 0.040 |
Why?
|
| DNA | 3 | 2011 | 1265 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 3828 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2006 | 822 | 0.040 |
Why?
|
| Interleukin-1alpha | 1 | 2020 | 4 | 0.040 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 14 | 0.040 |
Why?
|
| B-Cell Activating Factor | 1 | 2020 | 8 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 23 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1546 | 0.040 |
Why?
|
| Interferons | 1 | 2020 | 112 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 367 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1931 | 0.040 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2018 | 25 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1914 | 0.040 |
Why?
|
| Complement C1q | 1 | 2018 | 12 | 0.040 |
Why?
|
| Malaria | 1 | 2018 | 26 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 2018 | 9 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 153 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 317 | 0.030 |
Why?
|
| Cell Line | 2 | 2012 | 2464 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 220 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 469 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2018 | 184 | 0.030 |
Why?
|
| Haplotypes | 1 | 2018 | 647 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 585 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 19 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 53 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 464 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 57 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 174 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2016 | 211 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 92 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 361 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 131 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 103 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 42 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 356 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 790 | 0.020 |
Why?
|
| Cell Communication | 1 | 2014 | 216 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1994 | 884 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 711 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 391 | 0.020 |
Why?
|
| United States | 2 | 2018 | 7619 | 0.020 |
Why?
|
| Algorithms | 2 | 2010 | 1953 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 2011 | 17 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1275 | 0.020 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Feedback | 1 | 2012 | 131 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 98 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 220 | 0.020 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2010 | 20 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1243 | 0.020 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2010 | 14 | 0.020 |
Why?
|
| Clone Cells | 1 | 2010 | 219 | 0.020 |
Why?
|
| Aminopeptidases | 1 | 2010 | 14 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 189 | 0.020 |
Why?
|
| Germinal Center | 1 | 2010 | 62 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 578 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2010 | 84 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 126 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 167 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 78 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 179 | 0.020 |
Why?
|
| Pain | 1 | 2012 | 414 | 0.020 |
Why?
|
| Rituximab | 1 | 2010 | 128 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2010 | 260 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 282 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 287 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 961 | 0.020 |
Why?
|
| Child | 2 | 2010 | 7355 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 985 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 460 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 826 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 700 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2012 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2220 | 0.020 |
Why?
|
| Cell Movement | 1 | 2010 | 809 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 2910 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 1001 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1994 | 4560 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2715 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 1906 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 3220 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 3829 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1985 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3502 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1994 | 10164 | 0.010 |
Why?
|